• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Skaff Michael C

    4/2/26 7:34:11 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care
    Get the next $VVOS alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Skaff Michael C

    (Last)(First)(Middle)
    18000 MACK AVE

    (Street)
    GROSSE POINTE MICHIGAN 48230

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    Vivos Therapeutics, Inc. [ VVOS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    03/31/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    XForm filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Common Stock03/31/2026P1,044,777(1)A$1.341,044,777IBy V-CO Investors 3 LLC(2)
    Common Stock03/31/2026P308,848A$1.341,353,625IBy V-CO Investors 3 LLC(2)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Pre-Funded Warrant$0.000103/31/2026P429,95703/31/2026 (3)Common Stock429,957$1.34429,957IBy V-CO Investors 3 LLC(2)
    Series A Common Stock Warrant$1.0903/31/2026P1,783,58203/31/202603/31/2028Common Stock1,783,582$1.341,783,582IBy V-CO Investors 3 LLC(2)
    Series B Common Stock Warrant$1.0903/31/2026P1,783,58203/31/202603/31/2031Common Stock1,783,582$1.341,783,582IBy V-Co Investors 3 LLC(2)
    1. Name and Address of Reporting Person*
    Skaff Michael C

    (Last)(First)(Middle)
    18000 MACK AVE

    (Street)
    GROSSE POINTE MICHIGAN 48230

    (City)(State)(Zip)

    UNITED STATES

    (Country)

    Relationship of Reporting Person(s) to Issuer
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    1. Name and Address of Reporting Person*
    V-Co Investors 3 LLC

    (Last)(First)(Middle)
    18000 MACK AVE

    (Street)
    GROSSE POINTE MICHIGAN 48230

    (City)(State)(Zip)

    UNITED STATES

    (Country)

    Relationship of Reporting Person(s) to Issuer
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    Explanation of Responses:
    1. On March 31, 2026, V-Co Investors 3, LLC converted a bridge promissory note in the amount of $1,400,000 entered into between the reporting person and the Issuer into shares of the Issuer's common stock, based on $1.09 per share of Common Stock plus $0.25 per share in accordance with the Nasdaq minimum price rules.
    2. Michael C. Skaff serves as Managing Director of SP Manager LLC, the Manager of V-Co Investors 3 LLC. Michael C. Skaff and SP Manager LLC disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose.
    3. The Pre-Funded Warrant has a term ending on the complete exercise of the Pre-Funded Warrant.
    /s/ Michael C. Skaff, as Managing Director SP Manager LLC, Manager of V-Co Investors 3 LLC04/02/2026
    /s/ Michael C. Skaff, Individual04/02/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $VVOS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VVOS

    DatePrice TargetRatingAnalyst
    8/13/2021$11.00 → $10.00Buy
    Roth Capital
    More analyst ratings

    $VVOS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital reiterated coverage on Vivos Therapeutics with a new price target

    Roth Capital reiterated coverage of Vivos Therapeutics with a rating of Buy and set a new price target of $10.00 from $11.00 previously

    8/13/21 1:08:07 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Roth Capital reiterated coverage on Vivos Therapeutics with a new price target

    Roth Capital reiterated coverage of Vivos Therapeutics with a rating of Buy and set a new price target of $11.00 from $12.00 previously

    5/18/21 10:44:01 AM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    $VVOS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vivos Therapeutics Reports Full Year 2025 Financial Results

    Full Year 2025 revenue increased 16% Integration of The Sleep Center of Nevada and shift in business model support path to improved revenues, margins and cash flow Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., April 15, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea ("OSA"), today reported financial results and operating highlights for the full year ended December 31, 2025. Full Year 2025 Financial and Operating Summary R

    4/15/26 4:20:00 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call

    LITTLETON, Colo., April 15, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea ("OSA"), announced it plans to release its full year 2025 financial results after market close today, Wednesday, April 15, 2026. The Company will conduct a conference call at 5:00 pm (Eastern Time) to review the results and provide operational updates. Vivos encourages investors and other interested parties to join its conference call today at 5:00 p.m. Eastern time. Management w

    4/15/26 8:45:00 AM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners

    LITTLETON, Colo., April 07, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea ("OSA"), announced that it has closed on a private placement with V-Co Investors 3 LLC ("V-Co 3"), an affiliate of New Seneca Partners Inc. ("Seneca"). Gross proceeds of $2.25 million including the conversion of a previously announced bridge note of $1.4 million (prior to giving effect to an associated original issue discount). The private placement closed on March 31, 2026. This

    4/7/26 8:45:00 AM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    $VVOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider V-Co Investors 3 Llc

    3 - Vivos Therapeutics, Inc. (0001716166) (Issuer)

    4/10/26 4:54:28 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Skaff Michael C

    4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)

    4/2/26 7:34:11 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    New insider Johnson Gregg C claimed ownership of 3,997 shares (SEC Form 3)

    3 - Vivos Therapeutics, Inc. (0001716166) (Issuer)

    2/13/26 8:36:30 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    $VVOS
    SEC Filings

    View All

    Vivos Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)

    4/22/26 4:25:18 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Vivos Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)

    4/15/26 5:15:08 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Vivos Therapeutics Inc.

    10-K - Vivos Therapeutics, Inc. (0001716166) (Filer)

    4/15/26 5:00:25 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    $VVOS
    Financials

    Live finance-specific insights

    View All

    Vivos Therapeutics Reports Full Year 2025 Financial Results

    Full Year 2025 revenue increased 16% Integration of The Sleep Center of Nevada and shift in business model support path to improved revenues, margins and cash flow Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., April 15, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea ("OSA"), today reported financial results and operating highlights for the full year ended December 31, 2025. Full Year 2025 Financial and Operating Summary R

    4/15/26 4:20:00 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call

    LITTLETON, Colo., April 15, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea ("OSA"), announced it plans to release its full year 2025 financial results after market close today, Wednesday, April 15, 2026. The Company will conduct a conference call at 5:00 pm (Eastern Time) to review the results and provide operational updates. Vivos encourages investors and other interested parties to join its conference call today at 5:00 p.m. Eastern time. Management w

    4/15/26 8:45:00 AM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025

    Financial results highlighted by 78% sequential quarter over quarter revenue growth, showing the impact of the first full quarter of Sleep Center of Nevada operations Management to host conference call today at 5:00 pm ET to review results and provide operational updates LITTLETON, Colo., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company specializing in the delivery of highly effective diagnostic procedures and proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children), t

    11/19/25 4:20:00 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    $VVOS
    Leadership Updates

    Live Leadership Updates

    View All

    Vivos Therapeutics Adds to Management Team to Support Expansion and Growth

    LITTLETON, Colo., July 30, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ:VVOS) ("Vivos" or the "Company"), a pioneering medical technology company revolutionizing the treatment of obstructive sleep apnea (OSA) and snoring, today announced the appointments of Michael (Mike) E. Bruhn as its Executive Vice President of Business Operations Integration, and Dr. Terry Jones as its new Senior Vice President of Human Resources. These hires demonstrate Vivos' commitment to the successful implementation and expansion of its new sleep testing center and direct patient treatment operations, highlighted by Vivos' recent acquisition of The Sleep Center of Nevada and Vivos' ongoing, active e

    7/30/25 8:45:00 AM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    $VVOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Vivos Therapeutics Inc.

    SC 13G/A - Vivos Therapeutics, Inc. (0001716166) (Subject)

    11/14/24 4:49:30 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vivos Therapeutics Inc.

    SC 13G/A - Vivos Therapeutics, Inc. (0001716166) (Subject)

    11/14/24 4:05:24 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Vivos Therapeutics Inc.

    SC 13G - Vivos Therapeutics, Inc. (0001716166) (Subject)

    9/24/24 2:59:09 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care